Cancer drug pipeline is healthy, says head of oncologic drug approval for FDA
Explore this paper's citation graph
Summary
The US Food and Drug Administration is often depicted as an obstructionist bureaucracy that inhibits the development of life-saving cancer drugs, but according to an FDA insider, the real story on drug approval has remained untold.
- Type
- article
- Published
- 2008-08-02
- Cited by
- 3
- References
- 0
- OpenAlex
- https://openalex.org/W2940330427
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:145910182
Keywords
Drug, Cancer drugs, Food and drug administration, Medicine, Approved drug
References
No references recorded for this paper.
Cited by
- Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
- The Human Oocyte Preservation Experience (HOPE) a phase IV, prospective, multicenter, observational oocyte cryopreservation registry
- Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.
- Reproductive Biology and Endocrinology Open Access the Human Oocyte Preservation Experience (hope) a Phase Iv, Prospective, Multicenter, Observational Oocyte Cryopreservation Registry
Related papers
- Drug approval system questioned in US and Canada
- Making "me-too" drugs benefit the public.
- The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
- Breaking the FDA Monopoly
- Why more drugs are getting FDA approval
- US drug agency approves drug for low sexual desire in women
- FDA is urged to reverse its approval of new pain drug Zohydro ER
- Today's FDA.
- Breakthrough Drug Approval Process and Postmarketing ADR Reporting